DIABETES THERAPY TO IMPROVE MUSCLE MASS IN CF

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 Cf因胰岛素分泌缺陷而导致糖耐量受损的患者不进行常规的外源性胰岛素治疗，因为空腹血糖和糖化血红蛋白水平正常。这种做法忽略了胰岛素缺乏对蛋白质代谢的潜在有害影响。我们假设，长期使用胰岛素或口服降糖药将改善胰岛素缺乏、非糖尿病成人的蛋白质合成代谢。将进行一项多中心、前瞻性、安慰剂对照的双盲干预试验，用胰岛素、格列吡嗪、曲格列酮或安慰剂中的三种药物中的一种来治疗葡萄糖耐量异常的成年CF患者，为期6个月。我们将评估这些药物对蛋白质合成和分解、肺功能和身体成分的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. CF patients with impaired glucose tolerance due to defective insulin secretion are not routinely treated with exogenous insulin since fasting glucose and hemoglobin Alc levels are normal. This practice ignores the potentially detrimental effects of insulin deficiency on protein metabolism. We hypothesize that chronic treatment with either insulin or an oral hypoglycemic agent will lead to improved protein anabolism in insulin-deficient, non-diabetic CF adults. A multicenter, prospective, placebo-controlled, double-blinded intervention trail will be undertaken to treat glucose intolerant adult CF patients for six months with one of three agents: insulin, glipizide, troglitazone or placebo. We will evaluate the effects of these agents on protein synthesis and breakdown, pulmonary function, and body composition.